Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
870.48
-7.83 (-0.89%)
Streaming Delayed Price
Updated: 2:38 PM EST, Feb 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Eli Lilly
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Eli Lilly and Company (NYSE: LLY) Sets New 52-Week High in Tuesday Session
September 05, 2023
Via
Investor Brand Network
BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs
September 01, 2023
Via
Investor Brand Network
Exposures
Product Safety
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
September 01, 2023
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Eli Lilly and Company (NYSE: LLY) is a Stock Spotlight on 8/21
August 21, 2023
Via
Investor Brand Network
Eli Lilly and Company (NYSE: LLY) Climbs to New 52-Week High
August 08, 2023
Via
Investor Brand Network
Eli Lilly and Company (NYSE: LLY) Making Surprising Moves in Friday Session
July 14, 2023
Via
Investor Brand Network
Sex Hormones Market to See Huge Growth by 2028 : Novartis, Sanofi, AstraZeneca, Merck
August 30, 2023
Sex Hormones- Comprehensive Study by Type (Progesterone, Testosterone, Drospirenone), Application (Topical, Inhalation, Injection, Others) Players and Region - Global Market Outlook to 2027
Via
SBWire
Eli Lilly and Company (NYSE: LLY) Records 52-Week High Wednesday Morning
August 23, 2023
Via
Investor Brand Network
Why These 3 Large Caps Are Bucking the August Slump
August 22, 2023
The three largest S&P 500 outperformers of August are tacking on gains in a weak market, making them intriguing momentum plays to watch for the rest of 2023.
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Fossil Fuels
Interest Rates
US Equities
Addiction Treatment Market May See New Emerging Trends: Novartis, Pfizer, Sanofi
August 17, 2023
Pune, Maharashtra -- (SBWIRE) -- 08/17/2023 -- 2023-2031 Report on Global Addiction Treatment Market by Player, Region, Type, Application and Sales Channel is the latest research study released by HTF...
Via
SBWire
Polypeptide.ltd Announces Intent to Expand Tirzepatide and Retatrutide to Production Capacity of High-Quality Peptides
August 16, 2023
Via
Press Release Distribution Service
Eli Lilly and Company (NYSE: LLY) Sets New 52-Week High in Wednesday Session
August 16, 2023
Via
Investor Brand Network
Polypeptide.ltd Announces Intent to Expand Tirzepatide and Retatrutide to Production Capacity of High-Quality Peptides.
August 16, 2023
Moscow, Russia--(Newsfile Corp. - August 16, 2023) - Polypeptide.ltd, a frontrunner in delivering exceptional peptide services, proudly announces a substantial...
Via
Newsfile
Drinks, Chips & Drugs: A Surprising List of 10-Year Stock Winners
August 11, 2023
A handful of large caps have taken things to another level. These three stocks have blown past the herd — and may be market leaders for years to come.
Via
MarketBeat
Topics
Bankruptcy
Economy
Exposures
Economy
Financial
Legal
Novo Nordisk Soars To New High On Weight-Loss Drug Trial Results
August 09, 2023
Novo Nordisk's stock surged 16% on preliminary results of clinical trials showing its weight-loss drug Wegovy reduces risk of cardiovascular disease by 20%.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year’s End
August 09, 2023
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:CRDF),(NASDAQ:BDRX),(NASDAQ:DRUG),(NYSE:LLY) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions
August 08, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Blockbuster Drugs Market Projected to Show Strong Growth : Celgene, Bristol-Myers Squibb, Pfizer
August 03, 2023
Get an extensive Blockbuster Drugs Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.
Via
SBWire
Topics
Intellectual Property
Exposures
Intellectual Property
Rising Dividend Make Zoetis a Doggone Winner
August 03, 2023
Investors that typically focus on other large cap pharmaceutical plays may wish to consider an alternative bet on pets with shares of Zoetis.
Via
MarketBeat
MarketBeat Week in Review – 7/24 - 7/28
July 29, 2023
Investors continue to look for stocks to buy as inflation cools. As you prepare for another busy week, here are some of our top stories from this week
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
July 26, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lifestyle Drugs Market to See Huge Growth by 2028 : Alkermes, AstraZeneca, Pfizer, BMS
July 25, 2023
Lifestyle Drugs Comprehensive Study by Type (Depression, Dermatology, Sexual dysfunction, Obesity), Application (Children, Adults, Senior Citizens), Form (Tablets, External Use, Injection) Players and...
Via
SBWire
Exposures
Product Safety
Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush
July 24, 2023
A bid to acquire Versanis boosts Eli Lilly & Co. by 2.80% in the past week, as the competition to develop the most effective weight-loss drug intensifies.
Via
MarketBeat
Acumen Soars on Alzheimer's Study...Street Sees It Doubling
July 19, 2023
Will the $11.00 level be a double-top ceiling…or can Acumen Pharmaceuticals build momentum and climb towards its $25.00 IPO price?
Via
MarketBeat
Topics
Initial Public Offering
Exposures
Securities Market
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi
July 10, 2023
Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout.
Via
MarketBeat
Exposures
Product Safety
Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Eli Lilly, Genentech, BioNTech, Xencor, Celgene
July 05, 2023
Via
AB Newswire
Exposures
Product Safety
Alopecia Market expected to rise | Companies – Stiefel, GlaxoSmithKline, Eli Lilly and Company, Incyte Corporation, Energenesis Biomedical Co., expected to drive market
July 03, 2023
Via
AB Newswire
Inflammatory Bowel Disease Market expected to rise | Companies – Eli Lilly and Company, Gilead, Galapagos, Protagonist Therapeutics, Athos Therapeutics, expected to drive market
June 30, 2023
Via
AB Newswire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Names New COO, Announces Participation in Upcoming London Symposium
June 30, 2023
Via
Investor Brand Network
Exposures
Product Safety
Verve Therapeutics Gains 20.74% In June as Ark Funds Invest
June 30, 2023
Verve Therapeutics' efforts to eliminate cardiovascular disease through gene-editing treatments have momentum, as the stock gets a 20.74% boost in June.
Via
MarketBeat
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.